The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...

The College of Nurses of Ontario (CNO) welcomes the Ontario government's new bill to promote labour mobility in Canada, so we can continue to enable more nurses to provide safe ...

Stroke is the fourth leading cause of death among Hispanic men and the third leading cause for Hispanic women in the United States. Yet, according to CDC reports, only 58% of Hispanic adults can ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc, Pfizer Inc. and other drugmakers to overturn a judge who allowed more than 80,000 lawsuits to proceed to ...

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

GSK received approval from U.K.'s medicines regulatory body to bring its blood-cancer blockbuster candidate Blenrep back to the market, enabling the British pharma giant to expand its oncology ...

GSK said two of its vaccines obtained a positive recommendation from a U.S. body, aiming at tackling meningitis and the respiratory syncytial virus. The pharmaceutical company said Thursday that ...